Viz.ai today announced a collaboration with NICO Corporation to help improve the lives of patients with intracerebral hemorrhages. Intracerebral hemorrhage (ICH) is caused by bleeding in the brain tissue and is a life-threatening type of stroke. It accounts for up to 15% of all strokes and has high morbidity and mortality rates. Viz-ai’s technology can […]
Viz.ai
FDA clears Viz.ai algorithm for quantifying intracerebral hemmorhage
Viz.ai announced that it received FDA 510(k) clearance for its Viz ICH Plus algorithm for providing volume measurements of brain bleeds. Viz ICH Plus automates the process of identifying, labeling and quantifying the volume of segmentable brain structures on non-contrast computed tomography (NCCT) images. The company designed it to analyze intracranial hyperdensities, lateral ventricles and […]
FDA grants de novo nod to hypertrophic cardiomyopathy AI algorithm from Viz.ai
Viz.ai announced today that the FDA granted de novo approval to its Viz HCM module for detecting hypertrophic cardiomyopathy. San Francisco-based Viz.ai says this creates a new regulatory category for cardiovascular machine learning-based notification software. The company supports its algorithm’s deployment through a multi-year agreement with Bristol Myers Squibb. They struck that partnership deal in […]
FDA clears Viz.ai algorithm that detects abdominal aortic aneurysm
Viz.ai announced today that it received FDA 510(k) clearance for its algorithm that detects suspected abdominal aortic aneurysm (AAA). The company said in a news release that this marks the first FDA-cleared, AI-powered solution for detecting and triaging suspected AAA. Viz.ai’s AI algorithm automatically searches for the presence of an abdominal aortic aneurysm from any […]
Viz.ai partners with Bristol Myers Squibb on early hypertrophic cardiomyopathy detection
Viz.ai announced today that it entered into a multi-year agreement with Bristol Myers Squibb (NYSE:BMY) for detecting hypertrophic cardiomyopathy. The partnership seeks to deploy an AI algorithm and the Viz HCM provider workflow software. This can help identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. San Francisco-based Viz.ai […]
Viz.ai launches AI-powered vascular suite
Viz.ai announced that it launched its Viz Vascular Suite for detecting and triaging care for a range of suspected vascular conditions. Those conditions include pulmonary embolism, right heart strain, aortic dissection and abdominal aortic aneurysm (AAA). San Francisco-based Viz.ai submitted a 510(k) application to the FDA for the AI-powered software, according to a news release. […]
Viz.ai launches AI-powered radiology suite
Viz.ai announced today that it launched an AI-powered radiology suite for alerting radiologists and connecting care teams in real-time. San Francisco-based Viz.ai designed the suite to alert radiologists in their workflow of suspected diseases. It also prioritizes worklists and connects care teams while integrating into picture archiving and communications systems (PACS). This helps to securely […]
Viz.ai names Jieun Choe as chief marketing officer
Viz.ai this week announced it appointed Jieun Choe as chief marketing officer. Choe will report directly to CEO Chris Mansi and will oversee the global marketing strategy, brand and communications, product marketing and demand generation for the San Francisco-based company. “Jieun’s deep experience and proven track record in driving growth with expert execution will be […]
FDA clears new Viz.ai algorithm for measuring ventricles in identifying pulmonary embolism
Viz.ai announced today that it received FDA 510(k) clearance for its automated RV/LV ratio algorithm as part of the Viz PE solution. San Francisco-based Viz.ai designed its algorithm to quickly and accurately measure the diameter of the ventricles of the heart. The measurements provide the ratio of the maximum right ventricle (RV) diameter versus left […]
FDA clears Viz.ai’s algorithm that detects subdural hemorrhage
Viz.ai announced today that it received FDA 510(k) clearance for its Viz Subdural (SDH) artificial intelligence (AI) algorithm. San Francisco-based Viz.ai designed its Viz SDH algorithm to use AI to automatically detect subdural hemorrhage, enabling physicians to triage patients effectively and deliver optimal care. The company said in a news release that its Viz SDH […]
Viz.ai, Hyperfine partner on new MRI, workflow paradigm
Viz.ai announced today that it partnered with Hyperfine (Nasdaq:HYPR) to bring magnetic resonance imaging (MRI) to the patient’s bedside. San Francisco-based Viz.ai develops the Viz LVO, its flagship product designed to leverage advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat the patient. Hyperfine develops […]
